Skip to content

Epigenetic Regulation of BDNF in Schizophrenia

Epigenetic Regulation of BDNF and TrK B in Schizophrenic Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01021449
Enrollment
129
Registered
2009-11-30
Start date
2008-12-31
Completion date
2010-11-30
Last updated
2013-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BDNF, DNA Methylation, Suicide, Drug Responses.

Keywords

schizophrenia, BDNF, DNA methylation, histone modification

Brief summary

In this proposal, we will (1) detect the associations between BDNF and Trk B gene DNA methylation, histone modification, psychotic symptoms, obesity, suicide and antipsychotic drug responses in Taiwanese patients (2) discuss the possible mechanisms of epigenetic regulation of BDNF and Trk B in schizophrenia patients.

Detailed description

A total 160 subjects (80 subjects every year, including 40 healthy controls and 40 schizophrenia patients) will be recruited during a 2-year period. The first year, the baseline data of BDNF and Trk B DNA methylation, protein and mRNA levels in all subjects will be collected and the following 1 months data will also be collected in schizophrenia with antipsychotic drug treatments. The second year, the baseline data of BDNF and Trk B histone modification in all subjects will be collected.

Interventions

None listed

Sponsors

Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

\- 1\. The clinical screening and assessment in schizophrenic patients: 1. 40 schizophrenia patients will be recruited in psychiatric inpatients according to DSM-IV criteria (APA, 1994) by a structured interview (SCID). The assessment will be done by two senior psychiatrists. The intra-rater and inter-rater reliability will be done before this project started 2. age : 18-65 years old. 3. The patients had the ability to complete the written inform consent.。 4. The choice of antipsychotic drugs depended on the need of patients in natural treatment procedure. They included conventional drugs, eg.haloperidol 10-20 mg/day;SDA (serotonin dopamine antagonist) drug, eg. clozapine 100-400 mg/day or risperidone 3-6mg/day. The choice of the medication was according to the need of patients including previous responses and side effects. 5. PANSS (Positive and Negative Syndrome)(Kay, 1987,1988&1989) for positive, negative symptoms and severity. 6. Check body mass index (BMI): if BMI\<24: normal; 24\<BMI\<27: overweight; BMI\>27: obesity (Taiwan criteria, 2004). If the patients were overweight or obesity, the lipid profiles would be done and we would consult the experts to assess these patients. The condition for diet control and daily activity will be observed. If the condition was extremely abnormal, the case will be excluded. 7. Suicide behavior in tis study includes complete suicide and suicide attempt.

Exclusion criteria

1. The patients had systemic diseases, including metabolic, heart, and liver diseases。 2. The patients had received any drugs before entering this protocol. 3. The patients were heavy smokers or dependent on alcohol.

Design outcomes

Primary

MeasureTime frame
BDNF and Trk B DNA methylation, protein and mRNA levelsTwo years

Secondary

MeasureTime frame
the associations between BDNF and Trk B gene DNA methylation, histone modification, psychotic symptoms, obesity, suicide and antipsychotic drug responses in Taiwanese patientstwo years

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026